Israel-based Medison, a creator of a first-of-its-kind unified global commercialization platform that accelerates the launch of breakthrough therapies, has announced two key additions to its global leadership team: Shay Tamari as chief business officer (CBO) and Tali Mirsky as chief legal and compliance officer (CLCO). 19 June 2025
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Cambridge, UK-based Maxion Therapeutics today announced the appointment of Dr Stefan Härtle as chief development officer, effective immediately. 17 June 2025
Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organization (CMO) specializing in sterile manufacture of injectable drug products, has appointed Angelika Rublack as senior business development manager to support its expanding global client base and drive growth across several territories. 13 June 2025
US clinical-stage biotech Oncolytics Biotech today announced the appointment of Jared Kelly as chief executive (CEO) and a member of its board of directors. 11 June 2025
US ophthalmic gene therapy company Beacon Therapeutics, which is focused on restoring the vision of patients with blinding retinal diseases, has appointed Daniel Chung as chief medical officer (CMO). 9 June 2025
France-based SparingVision, a genomic medicine company focused on the treatment of retinal disease, has announced the appointment of Kalliopi ‘Kali’ Stasi, as chief medical officer, effective immediately. 9 June 2025
US cardiorenal-focussed drugmaker Ardelyx announced that Mike Kelliher, formerly executive vice president, corporate development and strategy, has been promoted to chief business officer, and James Brady has joined the company as chief human resources officer. 6 June 2025
Danish dermatology specialist LEO Pharma has appointed Helle Hedegaard Juhl as executive vice president for global people and corporate affairs (GPCA). 4 June 2025
Netherlands-based biotech VectorY Therapeutics, which is developing treatments for neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). 2 June 2025
Swiss biotech iOnctura has appointed Steven Sciuto as chief financial officer and Michelle Tsai as chief operating officer, marking a leadership shift as the company moves deeper into Phase II trials for its lead cancer candidate, roginolisib (IOA-244). 2 June 2025
US biotech Hillstar Bio has appointed Maude Tessier as chief operating officer and Shiva Krupa as vice president of program management, reinforcing its leadership bench ahead of a planned clinical entry for its lead autoimmune program in 2026. 29 May 2025
Swedish biotech Hansa Biopharma is preparing to reduce its headcount by around one-fifth as part of a restructuring plan aimed at sharpening operational focus and reducing costs. 27 May 2025
UK biotech Nucleome Therapeutics has appointed Bhavna Hunjan as chief business officer, a move that strengthens its leadership as it advances its pipeline of antibody therapies for inflammatory diseases. 27 May 2025
USA-based nonprofit CureDuchenne has announced the appointment of Brenda Wong as its new chief medical advisor (CMA), effective January 5, 2026. 22 May 2025
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024